Advances.

You’d be hard pressed to find many examples of more astounding oncologic advancements than that of immune checkpoint inhibition (ICI) for non-small cell lung cancer. This large retrospective study of outcomes at 280 cancer clinics across the US reveals that use of ICI shot up from <5% in 2015 to >45% in 2019 with similar use among patients of all ages, even those over 75. This was correlated with major shifts in survival times. Rate of survival at 2 years for patients 55 or younger was 36% in 2011 versus over 50% just 7 years later in 2018. By comparison, the benefit among those 75 and old was slightly less pronounced but still there with an improvement from 31 → 36% over the same period. | Voruganti, JAMA Oncol 2023